In light of Omnicare’s dropped bid for PharMerica, the Federal Trade Commission has voted 4-0 to dismiss its complaint to block the deal.
In the complaint, the FTC asserted that the merger would allow Omnicare to raise the price of drugs for Medicare Part D because the number of skilled nursing facilities receiving services from Omnicare would “dramatically increas[e],” thereby also increasing Omnicare’s bargaining power to raise the price of drugs to Part D health plans.
Source: Bloomberg
Related content: Interview with Jon Leibowitz
